Back to Search Start Over

Pravastatin and placental insufficiency associated disorders: A systematic review and meta-analysis.

Authors :
Hirsch A
Rotem R
Ternovsky N
Hirsh Raccah B
Source :
Frontiers in pharmacology [Front Pharmacol] 2022 Nov 09; Vol. 13, pp. 1021548. Date of Electronic Publication: 2022 Nov 09 (Print Publication: 2022).
Publication Year :
2022

Abstract

Background: Uteroplacental insufficiency associated disorders, such as preeclampsia, fetal growth restriction and obstetrical antiphospholipid syndrome, share pathophysiology and risk factors with cardiovascular diseases treated with statins. Objective: To evaluate pregnancy outcomes among women with uteroplacental insufficiency disorders who were treated with statins. Search Strategy: Electronic databases were searched from inception to January 2022 Selection Criteria: Cohort studies and randomized controlled trials. Data collection and analysis: Pooled odds ratios were calculated using a random-effects model; meta-regression was utilized when applicable. Main Results: The analysis included ten studies describing 1,391 women with uteroplacental insufficiency disorders: 703 treated with pravastatin and 688 not treated with statins. Women treated with pravastatin demonstrated significant prolongation of pregnancy (mean difference 0.44 weeks, 95%CI:0.01-0.87, p = 0.04, I <superscript>2</superscript> = 96%) and less neonatal intensive care unit admissions (OR = 0.42, 95%CI: 0.23-0.75, p = 0.004, I <superscript>2</superscript> = 25%). In subgroup analysis, prolongation of pregnancy from study entry to delivery was statistically significant in cohort studies (mean difference 8.93 weeks, 95%CI:4.22-13.95, p = 0.00) but not in randomized control studies. Trends were observed toward a decrease in preeclampsia diagnoses (OR = 0.54, 95%CI:0.27-1.09, p = 0.09, I = 44%), perinatal death (OR = 0.32, 95%CI:0.09-1.13, p = 0.08, I <superscript>2</superscript> = 54%) and an increase in birth weight (mean difference = 102 g, 95%CI: -14-212, p = 0.08, I <superscript>2</superscript> = 96%). A meta-regression analysis demonstrated an association between earlier gestational age at initiation of treatment and a lower risk of preeclampsia development (R <superscript>2</superscript> = 1). Conclusion: Pravastatin treatment prolonged pregnancy duration and improved associated obstetrical outcomes in pregnancies complicated with uteroplacental insufficiency disorders in cohort studies. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ identifier CRD42020165804 17/2/2020.<br /> (Copyright © 2022 Hirsch, Rotem, Ternovsky and Hirsh Raccah.)

Details

Language :
English
ISSN :
1663-9812
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in pharmacology
Accession number :
36438820
Full Text :
https://doi.org/10.3389/fphar.2022.1021548